What Merck does

Merck & Co., Inc. (NYSE: MRK) is a US-headquartered, publicly traded research-intensive biopharmaceutical company founded in 1891 in New York City by George Merck and now headquartered in Rahway, NJ. The company develops, manufactures, and commercializes prescription medicines and vaccines across six therapeutic franchises: oncology (anchored by Keytruda, the first anti-PD-1 therapy approved in 2014, deployed across 30+ tumor types and now combined with Welireg, Padcev, Trodelvy, sac-TMT, and Moderna's intismeran autogene), vaccines (Gardasil, Capvaxive, M-M-R, Pneumovax, Recombivax HB, Ervebo), infectious diseases (35+ years of HIV research, Lagevrio, AMR Action Fund), cardiometabolic and respiratory (Januvia, plus Verona Pharma-derived pulmonary assets), immunology (tulisokibart anti-TL1A acquired via the $10.8B Prometheus deal), and animal health (Bravecto, 70+ year franchise). The company operates Merck Animal Health as a separate global business unit and runs Merck Research Laboratories with approximately 24,700 R&D employees and $15.8B in R&D investment in 2025.

Merck's underlying technology platform is a multi-modality R&D engine spanning small molecules, biologics, antibody-drug conjugates, macrocyclic peptides, mRNA-based individualized neoantigen therapies, and AI-driven protein engineering, supported by the proprietary TEDDY family of AI models trained on more than 100 million single cells and partnerships with Tempus AI (45M+ de-identified patient records), Protillion Biosciences (Prot-MaP AI platform), and Google Cloud ($1B AI infrastructure partnership). The portfolio is anchored by Keytruda, which generated $8.0B in Q1 2026 (+8% YoY) and $8.37B in Q4 2025, and is being defended against the 2028 IV patent cliff through the September 2025 launch of subcutaneous Keytruda Qlex (with patent estate potentially extending to 2042) and aggressive M&A totaling $40B+ since 2023 across Cidara, Terns, Verona Pharma, Prometheus, Imago, Modifi Bio, Eyebiotech, Harpoon, Caraway, Acceleron, Pandion, and others.

Merck's business model is B2B/B2B2C pharmaceutical sales through direct specialty field forces (oncology, specialty pharma/infectious diseases, animal health), authorized distributor networks, co-promotion partnerships (Astellas for Padcev, Gilead for Trodelvy and once-weekly oral HIV), and patient assistance programs. Revenue is overwhelmingly generated by pharmaceutical and vaccine product sales, with collaboration/licensing income (Moderna, Gilead, Daiichi Sankyo), animal health sales, and philanthropic channels (Merck Medical Outreach Program, Impact Venture Fund) as supplementary streams. 2026 full-year revenue guidance is $65.5-67.0B. Merck also reaches >450M people with medicines and vaccines across 92% of countries, with notable impact-investing and global health programs including the 35-year Mectizan donation for river blindness, Merck for Mothers (>9M women in 48 countries), and a $55M Impact Venture Fund.

Name

Merck

Legal name

Merck & Co., Inc., Rahway, NJ, USA

Website

https://merck.com

Company type

Public

Founded year

1891

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merck & Co., Inc. is a US-headquartered biopharmaceutical company that develops and commercializes prescription medicines and vaccines across oncology, vaccines, infectious diseases, immunology, cardiometabolic, and animal health, anchored by the Keytruda immuno-oncology franchise and a global multi-modality R&D engine.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (54194), Veterinary Services (541940)

SIC

Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Veterinary Vaccines (Biologics) (HLAMAEAL)

akta.pro secondary industries

Veterinary Vaccines (HLAIAEAH), Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

Keywords

• Biopharmaceutical medicines
• Oncology therapies
• Vaccines and prevention
• Immuno-oncology drugs
• Animal health products

Headquarters

HQ city

Rahway

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical product sales (human health): Primary revenue stream from sales of patented prescription medicines and vaccines including Keytruda, Gardasil, Januvia, Keytruda Qlex, Welireg, Capvaxive, and a broad oncology, vaccines, infectious disease, and cardiometabolic/respiratory portfolio. Keytruda alone generated $8.0B in Q1 2026 (8% YoY growth) and $8.37B in Q4 2025. 2026 revenue guidance: $65.5-67.0B.
2. Animal Health product sales: Merck Animal Health sells veterinary pharmaceuticals, vaccines, and health management solutions/digital products for livestock and companion animals (e.g., Bravecto). Operates as a separate global business unit with its own distribution network and 70+ year history.
3. Collaboration and licensing income (incl. co-development milestone payments): Revenue from strategic co-development partnerships including Moderna (mRNA-4157), Gilead (islatravir/lenacapavir once-weekly HIV), Daiichi Sankyo (ADC programs), and Astellas (Padcev combination). Includes upfront payments, R&D milestones, and royalty/profit-share arrangements.
4. Merck Medical Outreach Program (product donations): Charitable product donation program (65+ years) channeling pharmaceuticals and vaccines through qualified NGO partners (AmeriCares, CMMB, Direct Relief, MAP International, Partners In Health, Project HOPE) to low- and middle-income countries and disaster relief. Not a commercial revenue stream but tracked for impact metrics.
5. Investment income (Impact Venture Fund): $55M+ of venture capital investments via Impact Venture Fund into funds/companies addressing health access in LMICs. Returns are recycled into new investments; impact reaches 35M+ people cumulatively since 2018.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Core offering

Merck is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines and vaccines for human health, alongside veterinary pharmaceuticals, vaccines, and connected health technologies for animal health through its Merck Animal Health division. Its commercial portfolio is anchored by the KEYTRUDA immuno-oncology franchise and combination regimens, a broad vaccines portfolio (GARDASIL, CAPVAXIVE, ERVEBO, M-M-R, PNEUMOVAX, RECOMBIVAX HB), the Lagevrio COVID-19 antiviral, JANUVIA for Type 2 diabetes, tulisokibart for ulcerative colitis, and BRAVECTO and other parasiticide products for companion animals.

Product overview

Merck operates a multi-franchise biopharmaceutical portfolio rather than a single unified product, anchored by the KEYTRUDA immuno-oncology franchise — including the IV KEYTRUDA backbone, the subcutaneous KEYTRUDA QLEX co-formulation, and combination partners such as WELIREG, Padcev, Trodelvy, and Moderna's intismeran autogene (mRNA-4157). Its vaccines franchise spans GARDASIL (HPV), CAPVAXIVE (pneumococcal), ERVEBO (Ebola Zaire), M-M-R, PNEUMOVAX, and RECOMBIVAX HB, while infectious-disease and cardiometabolic franchises include Lagevrio for COVID-19 and JANUVIA for Type 2 diabetes. Animal Health is represented by BRAVECTO and is being expanded into biodevices via the announced TARGAN acquisition. Pipeline and acquired assets layered on top include tulisokibart (anti-TL1A, ex-Prometheus), TERN-701 (ex-Terns), CD388 (ex-Cidara), the islatravir + lenacapavir HIV combination with Gilead, and the personalized cancer vaccine program with Moderna. Underpinning this portfolio is M-Trust, Merck's physical authentication technology, which integrates with The Hashgraph Group's TrackTrace Digital Product Passport on the Hedera network to secure regulated pharmaceutical supply chains, and Merck's broader AI stack (TEDDY models, Prot-MaP via Protillion, and expanded AI partnerships) which supports discovery and translational research across the franchise.

Differentiator

Problem solved

Functional benefit

Brands

• Merck Animal Health: Global animal health business unit offering veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals, with over 70 years of history.
• Merck Foundation
• Merck for Mothers

Products and services

• KEYTRUDA (pembrolizumab) Merck's flagship anti-PD-1 checkpoint inhibitor, initially FDA approved in 2014 and used across more than two dozen tumor types as monotherapy and backbone of multiple combination regimens (with Padcev, WELIREG, Trodelvy, mRNA-4157). Q1 2026 sales of $8.0B; Q4 2025 sales of $8.37B.
• KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Subcutaneous co-formulation of pembrolizumab with the hyaluronidase enzyme berahyaluronidase alfa-pmph, designed to shorten administration time versus IV KEYTRUDA while preserving efficacy; approved alongside IV KEYTRUDA in combination regimens such as the first-line TNBC regimen with Trodelvy.
• WELIREG (belzutifan) HIF-2α inhibitor approved in combination with KEYTRUDA for adjuvant and advanced renal cell carcinoma and used as the combination backbone in Merck's expanding RCC franchise. 41% sales growth to $716M in 2025; Leerink projects $3.4B by 2028.
• Tulisokibart (MK-7240) Anti-TL1A monoclonal antibody acquired through Merck's Prometheus Biosciences transaction; reported positive Phase 3 results in moderate-to-severe ulcerative colitis in June 2026 (first anti-TL1A biologic to demonstrate Phase 3 UC clinical remission), positioning it as a late-stage immunology candidate being evaluated across 7 disease indications.
• JANUVIA (sitagliptin) DPP-4 inhibitor for the treatment of Type 2 diabetes, one of Merck's established cardiometabolic franchises facing patent expiration contributing to the ~$2.5B 2026 generic/Medicare impact.
• GARDASIL Merck's HPV vaccine, a foundational product in the vaccines franchise for the prevention of HPV-related cancers and diseases. Subject of Merck's Gardasil lawsuit settlement of approximately $50 million.
• CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine; originally approved for adults and subsequently expanded by FDA to at-risk pediatric populations; covers ~79% of invasive pneumococcal disease serotypes in at-risk children.
• ERVEBO Merck's Ebola Zaire vaccine, used as part of Merck's infectious-disease vaccines portfolio.
• M-M-R (measles-mumps-rubella vaccine) Combination measles-mumps-rubella vaccine, a long-established Merck vaccine product.
• PNEUMOVAX Pneumococcal polysaccharide vaccine for adult pneumococcal disease prevention.
• RECOMBIVAX HB Merck's recombinant hepatitis B vaccine.
• Lagevrio (molnupiravir) Oral antiviral authorized for the treatment of mild-to-moderate COVID-19 in at-risk adults; also being offered as a potential countermeasure in a WHO-led DRC Ebola trial.
• BRAVECTO Flagship Merck Animal Health parasiticide brand for dogs and cats providing long-duration flea and tick protection.
• TERN-701 Allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), obtained through Merck's acquisition of Terns Pharmaceuticals and integrated into Merck's oncology pipeline.
• CD388 Long-acting influenza prevention candidate acquired via the announced acquisition of Cidara Therapeutics, intended to anchor Merck's antiviral franchise.
• Islatravir + lenacapavir (oral HIV combination) Once-weekly oral combination of Merck's islatravir (nucleoside reverse transcriptase translocation inhibitor) and Gilead's lenacapavir for heavily treatment-experienced adults with multidrug-resistant HIV-1; reported positive Phase 3 results in June 2026 and, if approved, would be the first long-acting oral HIV treatment taken once weekly.
• Intismeran autogene (mRNA-4157 / V940) Personalized neoantigen mRNA cancer vaccine co-developed with Moderna, combined with KEYTRUDA in resected high-risk melanoma; Phase 2b KEYNOTE-942 five-year data showed 49% reduction in recurrence or death and 59% reduction in distant metastasis; 9 Phase 2/3 trials underway across melanoma, NSCLC, bladder cancer, and RCC.

Quantifiable outcome

• 35% reduction in risk of disease progression or death with Keytruda + Trodelvy vs Keytruda + chemo in 1L PD-L1+ mTNBC (median PFS 11.2 vs 7.8 months)
• +6 more outcomes

Named customers10 records

Segments8 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability10 records

Feature9 records

Partnerships

33 partnerships are on record, tiered flagship, core and minor.

• Gilead SciencesflagshipStrategic or Co-development Partner · 24 June 2026Multiple co-development programs: (1) Trodelvy (sacituzumab govitecan-hziy) + Keytruda combination approved in 1L PD-L1+ metastatic TNBC (June 2026) and under EU review; (2) Once-weekly oral HIV treatment islatravir/lenacapavir met primary efficacy in Phase 3 ISLEND-1 and ISLEND-2; (3) Lung cancer combo trial KEYNOTE-D46/EVOKE-03 discontinued. Relationship is mutual co-development.
• Astellas PharmaflagshipStrategic or Co-development Partner · 24 June 2026Co-promotion of Padcev (enfortumab vedotin) + Keytruda (pembrolizumab) combination as perioperative treatment for adults with resectable muscle-invasive bladder cancer who are ineligible for cisplatin. EU approval June 2026 based on Phase 3 KEYNOTE-905 showing 60% reduction in EFS events and 50% reduction in death risk vs surgery alone.
• Daiichi SankyocoreStrategic or Co-development Partner · 24 June 2026Co-development of ADC programs including ifinatamab deruxtecan (B7-H3 ADC). Daiichi appointed John Tsai as head of R&D to execute 5-year plan to become a top-5 oncology company by 2035. Merck is referenced as a key ADC partner alongside AstraZeneca.
• Mapp BiopharmaceuticalminorStrategic or Co-development Partner · 24 June 2026Merck is offering its antiviral molnupiravir (Lagevrio) as a potential countermeasure in a WHO-led DRC Ebola trial testing MBP134 and remdesivir against Bundibugyo ebolavirus. Outbreak has caused 1,094 confirmed cases and 277 deaths.
• MaeminorGTM or Marketing Partner · 23 June 2026Multi-state partnership through Merck for Mothers initiative to expand and sustain the community-based doula workforce in California, Georgia, Illinois, and Texas. Provides doula training, professional development, and administrative support to help community doulas achieve Medicaid participation.
• ExelixisminorStrategic or Co-development Partner · 22 June 2026Clinical development collaboration for the STELLAR-316 trial evaluating zanzalintinib combination in metastatic colorectal cancer.
• Nectin TherapeuticsminorStrategic or Co-development Partner · 17 June 2026Clinical combination partnership evaluating NTX1088 (first-in-class anti-CD155 antibody) + Keytruda in 91 patients with advanced solid tumors; Phase 1a/1b data presented at ASCO 2026.
• Protillion BiosciencescoreTechnology or Integration · 16 June 2026Multi-target drug discovery collaboration and license agreement. Merck gets access to Prot-MaP AI platform for designing biologic therapies across multiple undisclosed indications. Protillion eligible for up to $510M in R&D and commercial milestone payments.
• Terns PharmaceuticalsflagshipStrategic or Co-development Partner · 15 June 2026Merck acquiring Terns Pharmaceuticals for approximately $6.7B (announced March 2026; ~$5.7B net of acquired cash; 31% premium to 60-day VWAP). Brings lead candidate TERN-701, an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor in Phase 1/2 for chronic myeloid leukemia (FDA Orphan Drug Designation March 2024). Expected to close in Q2 2026.
• RochecoreTechnology or Integration · 11 June 2026Companion diagnostic partnership: Roche's VENTANA MMR RxDx Panel received EU IVDR approval as a companion diagnostic for Keytruda (Merck) across 5 cancer types and 6 indications, alongside IMFINZI/LYNPARZA (AstraZeneca) and JEMPERLI (GSK). Validates patient selection for Keytruda therapy.
• TarganminorStrategic or Co-development Partner · 11 June 2026Definitive agreement by Merck Animal Health to acquire Targan, a privately held company developing biodevice solutions for the poultry industry. Deal expected to close in Q3 2026 pending regulatory approvals.
• Agilent TechnologiescoreTechnology or Integration · 2 June 2026Co-developed PD-L1 IHC 22C3 pharmDx companion diagnostic on Dako Omnis platform for Keytruda. FDA approved expansion to 4 additional cancer types (esophageal SCC, TNBC, cervical, gastric/GEJ adenocarcinoma), enabling consolidated PD-L1 testing across tumor types.
• ModernaflagshipStrategic or Co-development Partner · 1 June 2026Co-development of intismeran autogene (mRNA-4157) individualized neoantigen therapy combined with Keytruda. 5-year Phase 2b KEYNOTE-942 data showed 49% reduction in melanoma recurrence/death and 59% reduction in distant metastasis. 9 total Phase 2/3 trials underway across melanoma, NSCLC, bladder cancer, and renal cell carcinoma. Phase 3 INTerpath trial ongoing.
• Kelun-BiotechcoreStrategic or Co-development Partner · 1 June 2026Co-developer of sacituzumab tirumotecan (sac-TMT) TROP2-directed antibody-drug conjugate. Phase 3 data in 1L NSCLC showed 80.4% 1-year OS with sac-TMT+Keytruda vs 68.9% for Keytruda monotherapy; 70% ORR; 65% reduced tumor progression risk. Phase 3 TroFuse-005 in endometrial cancer met OS and PFS endpoints.
• City Cancer ChallengecoreGTM or Marketing Partner · 15 May 2026Expanded global partnership to strengthen women's cancer care. Initiative aims to reach more than 300,000 women living with cancer around the world by 2030.
• Cidara TherapeuticsflagshipStrategic or Co-development Partner · 14 November 2025Merck agreed to acquire Cidara Therapeutics for approximately $9.2B to develop CD388, a long-acting antiviral drug for influenza prevention (Phase III). Part of Merck's strategy to diversify beyond Keytruda's patent cliff.
• Imago BioSciencescoreStrategic or Co-development Partner · 22 November 2022Merck acquired Imago BioSciences for approximately $1.35B in all-cash deal (closed Q1 2023) to strengthen pipeline in hematology through development of medicines for myeloproliferative neoplasms (MPNs) and other bone marrow diseases.
• AmeriCarescoreOthersQualified NGO partner receiving Merck pharmaceutical and vaccine donations through the Merck Medical Outreach Program (65+ years) for humanitarian assistance in LMICs and disaster relief worldwide.
• Direct ReliefcoreOthersQualified NGO partner in the Merck Medical Outreach Program receiving pharmaceutical and vaccine donations for humanitarian use in LMICs.
• Partners In HealthcoreOthersQualified NGO partner receiving Merck Medical Outreach Program donations of medicines and vaccines for humanitarian programs in low- and middle-income countries.
• Project HOPEcoreOthersQualified NGO partner in Merck's Medical Outreach Program; receives pharmaceutical and vaccine donations for distribution in LMICs and disaster relief.
• MAP InternationalcoreOthersQualified NGO partner in Merck's Medical Outreach Program receiving pharmaceutical donations for distribution in low- and middle-income countries.
• CMMB (Catholic Medical Mission Board)coreOthersQualified NGO partner receiving Merck Medical Outreach Program donations of pharmaceuticals and vaccines for humanitarian assistance in developing countries.
• UNICEF USminorOthersImpact investing partnership supporting acceleration of critical health care commodities for vulnerable children in limited-resource settings.
• Tempus AIcoreTechnology or IntegrationData partnership with AI-enabled precision medicine company. Leverages 45M+ de-identified patient records and 500+ petabytes of data. Individual deal values reaching up to $320M. AstraZeneca and GSK also cited as Tempus partners.
• Prometheus BiosciencesflagshipStrategic or Co-development PartnerAcquired by Merck for $10.8-11B in 2023. Lead program tulisokibart (MK-7240), an anti-TL1A monoclonal antibody, met primary endpoint of clinical remission at week 12 in Phase 3 ATLAS-UC induction-only study for ulcerative colitis - first anti-TL1A biologic to achieve this milestone. Being evaluated across 7 disease indications.
• N.C. A&T (North Carolina Agricultural and Technical State University)minorStrategic or Co-development PartnerPartnership to launch a collaborative biotechnology learning center as a foundation for future talent development.
• PfizercoreStrategic or Co-development PartnerPfizer is continuing a late-stage study testing sigvotatug vedotin in combination with Merck's Keytruda as a first-line treatment for NSCLC. Combinatorial use of Keytruda as backbone in lung cancer studies.
• Ukko LaboratoriesminorStrategic or Co-development PartnerCooperation agreement covering Ukko's RNA-based peanut allergy therapy (Ukko18) and Aulos Bioscience's AI-designed cancer immunotherapy. Ukko and Aulos Biolojic Design have raised over $200M for research combined.
• Google CloudcoreTechnology or Integration$1B partnership with Google Cloud for AI infrastructure, referenced alongside Merck's broader AI agenda including the Protillion Biosciences AI drug discovery collaboration.
• Questex / Fierce Life Sciences (Partnerships with Sites Summit)minorGTM or Marketing PartnerMerck executives participating in the 2nd annual Partnerships with Sites Summit (September 14, 2026, Boston), alongside Eli Lilly, Biogen, Novartis, AstraZeneca, Sanofi, and Takeda to address clinical trial system challenges costing the industry ~$50B annually.
• AMR Action FundcoreStrategic or Co-development PartnerMerck committed $100M over 10 years to the AMR Action Fund, a partnership of 20+ leading pharmaceutical companies, philanthropies, and organizations aimed at bringing 2-4 novel antibiotics to patients and physicians by 2030.
• Gilead Sciences (HIV clinical collaboration)flagshipStrategic or Co-development PartnerClinical trials for HIV treatment involving islatravir/lenacapavir (once-weekly oral HIV treatment) - if approved, would be the first long-acting oral HIV treatment taken once weekly. Per Cantor Fitzgerald, positive outcomes were observed.

Scale indicators15 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Bristol Myers Squibb: Direct PD-1/PD-L1 oncology competitor with Opdivo (nivolumab) competing head-to-head with Keytruda across multiple tumor types. Similar large-cap biopharma profile with comparable oncology, immunology, and cardiovascular franchises.
• Roche: Direct oncology competitor with Tecentriq (PD-L1) plus deep companion diagnostic footprint. Roche's VENTANA MMR RxDx Panel is a CDx for Keytruda, illustrating the intertwined competitive and partnership dynamics across immuno-oncology.
• AstraZeneca: Direct PD-L1 competitor (Imfinzi/durvalumab) and ADC platform partner alongside Daiichi Sankyo. Competes with Merck in lung, breast, and GI oncology while sharing the ADC modality frontier.

Broad incumbents

• Pfizer: Comparable large-cap biopharma with overlapping oncology, vaccines, and infectious disease franchises. Currently combining its sigvotatug vedotin with Merck's Keytruda in NSCLC trials, illustrating both competitive overlap and partnership dynamics.
• Eli Lilly: Similar large-cap biopharma competing across oncology, immunology, cardiometabolic, and neuroscience. Lilly's tirzepatide/Verona-style acquisition strategy and oncology pipeline expansion parallel Merck's M&A-driven approach.
• Novartis: Comparable global biopharma with strong oncology (Pluvicto, Kisqali), cardiovascular, and immunology franchises. Competes directly in radioligand therapy and CDK4/6 inhibitor spaces adjacent to Merck's oncology pipeline.
• Johnson & Johnson: Diversified large-cap with a sizable Innovative Medicine pharmaceutical segment overlapping Merck's oncology, immunology, and infectious disease franchises. J&J's Darzalex and oncology pipeline compete for the same oncologists and indications.
• AbbVie: Comparable large-cap biopharma that has navigated a major Humira patent cliff via Skyrizi/Rinvoq and aggressive M&A (Allergan, ImmunoGen, Cerevel). Provides a useful precedent for managing large patent-cliff transitions.
• Sanofi: Global biopharma with overlapping immunology (Dupixent), vaccines, and rare disease franchises. Competes with Merck in inflammatory bowel disease and is an established vaccines peer.
• GSK: Direct competitor in vaccines (Shingrix, HPV, pneumococcal), HIV (ViiV Healthcare), and oncology (Jemperli PD-1 inhibitor). GSK's oncology pipeline competes with Merck in endometrial and other gynecologic cancers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/merck
• YouTubeyoutube.com/user/Merck
• Facebookfacebook.com/MerckInvents
• LinkedInlinkedin.com/company/merck
• Instagraminstagram.com/merck

Revenue estimate

Valuation estimate

Number of profiles

Profiles27 records

Subsidiaries6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A42 records

Investments35 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck